Democritus University of Thrace (DUTH)
Μελέτη παραγόντων ανταπόκρισης στη θεραπεία ασθενών με χρόνια ηπατίτιδα C: ο κλινικός ρόλος της HCV - ARF / CORE +1 πρωτεΐνης
Abstract
dc:descriptionIt has been suggested that hepatitis C virus (HCV) core+1 protein plays a role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. To investigate its relationship with the outcome of HCV standard combination therapy with peginterferon-α plus ribavirin, we screened 139 consecutive HCV patients (119 with chronic HCV infection and 20 who spontaneously cleared HCV) for the presence of anti-core+1 antibodies (Abs). In addition, liver fibrosis was determined by Fibroscan in all but one patients.Twenty-nine patients were cirrhotic (stiffness >12.5 kPa, F4 METAVIR), all of them with mild liver cirrhosis (Child-Pugh score A). Eighty-six of 139 patients were treatment-experienced with standard combination therapy. Fifty of them had achieved a sustained virological response, while 36 were non-responders. The prevalence of anti-core+1 Abs in patients with chronic HCV infection was 22.69% (27/119 patients): 18% (9/50 patients) in responders and 36.11% (13/36 patients) in non-responders (P=0.050). Five (17.24%) of the 29 cirrhotic patients and 22 (24.72%) of the 89 non-cirrhotic patients were positive for anti-core+1 Abs (P=0.405). Furthermore, the presence of anti-core+1 Abs correlated with the poor response interleukin (IL) 28B genotype TT (P=0.040). No correlation between spontaneous clearance and anti-core+1 Abs was observed (P=0.088).In conclusion, the presence of anti-core+1 Abs might be correlated with the poor response IL28B TT genotype and may negatively affect the outcome of standard combination treatments in HCV patients, suggesting that core+1 may play a biological role in the course of HCV infection.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Mylopoulou, Theodora
- Μυλοπούλου, Θεοδώρα
Subjects
dc:subject × 18- Core+1/ARF πρωτεΐνη
- IL28B
- IFNλ4
- Προγνωστικοί παράγοντες στη θεραπεία του HCV
- Core+1/ARF protein
- Prognostic factors for HCV treatment
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ηπατολογία
- Κλινική ιατρική, γενικά
- Επιστήμες Υγείας
- Λοιμώδη νοσήματα
- Clinical Medicine
- Medical and Health Sciences
- Hepatology
- Clinical medicine, general
- Health Sciences
- Infectious Diseases
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45206